Background: There have been postmarketing reports of adverse cardiovascular events
associated with the use of varenicline, a widely used smoking cessation drug. We conducted …

Background Varenicline is an efficacious smoking‐cessation drug. However, previous meta‐
analyses provide conflicting results regarding its cardiovascular safety. The publication of …

Objective To examine the risk of treatment emergent, cardiovascular serious adverse events
associated with varenicline use for tobacco cessation. Design Meta-analysis comparing …

Background—Smoking cessation is a key component of secondary cardiovascular disease
prevention. Varenicline, a partial α4β2 nicotinic acetylcholine receptor agonist, is effective …

Abstract Background: Varenicline (Chantix®, Champix®) has shown efficacy and tolerability
as an aid to smoking cessation. In postmarketing surveillance, neuropsychiatric symptoms …

Background Varenicline is an effective pharmacotherapy to aid smoking cessation.
However, its use is limited by continuing concerns about possible associated risks of serious …

Varenicline is a recently developed medication for smoking cessation, which has been
available on prescription since 2006. It is a selective nicotinic acetylcholine receptor partial …

Objective: We assessed the safety of long-term varenicline administration for smoking
cessation. Methods: In this randomized, double-blind, multicenter trial, eligible adult smokers …

Varenicline is an orally administered small molecule with partial agonist activity at the α4β2
nicotinic acetylcholine receptor. Varenicline was approved by both the US FDA and the …

Background: Varenicline acts as a partial agonist/antagonist with affinity and selectivity for
α4 β2 nicotinic acetylcholine receptors. This activity at the nicotine-receptor level may help …